Keros Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Keros Therapeutics generated cash of -$124,508,000, which is less than the previous year. Cash used in financing activities reached the amount of $178,956,000 last year. Net change in cash is therefore $51,984,000.
Cash Flow
| 2018 | 7.04M | -217K | 11.46M |
|---|---|---|---|
| 2019 | -15.99M | -271K | 14K |
| 2020 | -36.89M | -294K | 296.04M |
| 2021 | -62.14M | -1.02M | 28.55M |
| 2022 | -70.06M | -1.24M | 120.30M |
| 2023 | -124.50M | -2.46M | 178.95M |
KROS Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 280.37M | 231.36M | 265.99M | 7.13M | 23.39M | 5.10M |
Operating activities | ||||||
Net income | -152.99M | -104.67M | -58.74M | -45.36M | -12.33M | -1.33M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 815K | 674K | 378K | 278K | 208K | 153K |
Stock-based compensation expense | 28.76M | 18.68M | 11.72M | 4.09M | 59K | 0 |
| Deferred income tax benefit | 28.76M | 18.68M | 11.72M | 4.09M | 59K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -143K | 18M | -18M | 922K | -552K | 0 |
Inventories | -4.50M | 0 | 1.04M | -922K | 552K | 0 |
Accounts payable | 1.61M | -408K | 1.48M | 61K | 1.31M | -2K |
Cash generated by operating activities | -124.50M | -70.06M | -62.14M | -36.89M | -15.99M | 7.04M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2.46M | -1.24M | -1.02M | -294K | -271K | -217K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -2.46M | -1.24M | -1.02M | -294K | -271K | -217K |
Financing activities | ||||||
Common Stock Issued | 175.82M | 119.57M | 28.17M | 243.20M | 14K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 178.95M | 120.30M | 28.55M | 296.04M | 14K | 11.46M |
Net Change In Cash | 51.98M | 49.00M | -34.62M | 258.85M | -16.25M | 18.28M |
Cash at end of period | 332.35M | 280.37M | 231.36M | 265.99M | 7.13M | 23.39M |
| Data source | Data source | Data source |